# Healome Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/healome-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Birmingham, UK
- Website: www.healometx.com/
- Total disclosed funding: $2.7M
- Latest round: Seed (Oct 15, 2025)
- Investors on record: 4

## About

Based in Birmingham, UK, Healome Therapeutics specializes in developing advanced ocular drug delivery systems, focusing on proprietary eye drop technology to enhance therapeutic efficacy for ocular diseases.Healome Therapeutics Ltd, founded in 2021, is dedicated to innovative ocular drug delivery solutions. The company has completed one deal and recently raised GBP 2 million in Seed funding on July 7, 2026, led by Empirical Ventures and supported by investors including DEBRA Research, SFC Capital, and others. The company operates out of Birmingham, UK, and is led by a founder with a background in previous entrepreneurial ventures.Healome Therapeutics specializes in the development of innovative ocular drug delivery systems. The company focuses on its proprietary eye drop matrix technology, which initially behaves like a liquid and restructures to create a clear, lubricating, and protective matrix on the ocular surface. This addresses the limitations of conventional eye drops, which clear quickly from the surface, enhancing therapeutic effects and longevity. Healome's products target a range of ocular surface conditions, delivering both small molecules and complex biologics to individuals with ocular diseases and healthcare providers seeking improved treatment options. The company markets its innovative solutions globally, emphasizing regions with increasing demand for advanced eye care.Healome Therapeutics generates revenue through the commercialization of its ocular drug delivery products. The company engages in B2B transactions, partnering with healthcare providers and pharmaceutical companies who purchase its eye drop matrix technology for clinical use. Although specific pricing information is not disclosed, the pricing structure reflects the advanced formulation and delivery capabilities of Healome's products. Strategic collaborations are essential for expanding market reach and addressing the challenges of ocular health management.Healome Therapeutics plans to utilize the GBP 2 million raised in Seed funding for pre-clinical work, manufacturing scale-up, regulatory engagements, and first-in-human studies set for 2027. The company aims to expand its market presence by launching new products designed to enhance ocular health and targeting regions with increasing demand for advanced eye care solutions.

## Funding rounds

- Seed, Oct 15, 2025, $2.7M — SFC Capital, Empirical Ventures, Oshen, DEBRA Research

## Investors

- SFC Capital (https://capitalatlas.ai/funds/sfc-capital) — Seed
- Empirical Ventures (https://capitalatlas.ai/funds/empirical-ventures) — Seed
- Oshen — Seed
- DEBRA Research — Seed